Blue Jet Healthcare
411.45
+4.75(+1.17%)
Market Cap₹7,137.23 Cr
PE Ratio20.04
IndustryHealthcare
Company Performance:
1D+1.17%
1M-21.59%
6M-48.02%
1Y-50.06%
5Y-0.47%
View Company Insightsright
More news about Blue Jet Healthcare
12Sept 25
Blue Jet Healthcare Promoter Offloads 6.19% Stake to Meet Public Shareholding Norms
Akshay Bansarilal Arora, a key promoter of Blue Jet Healthcare Limited, has sold 10,734,529 equity shares (6.19% stake) through an Offer for Sale (OFS) mechanism. The sale, conducted on September 10 and 11 on both BSE and NSE, reduces the promoter group's shareholding from 86.00% to 79.81%, while increasing public shareholding from 14.00% to 20.19%. This move aims to comply with SEBI's minimum public shareholding requirements. The OFS was facilitated by a consortium of brokers including ICICI Securities, Kotak Securities, Motilal Oswal Financial Services, and Nomura Financial Advisory and Securities (India) Private Limited.
 no imag found
09Sept 25
Blue Jet Healthcare Co-Promoter Akshay Arora to Offload 3.42% Stake via OFS
Akshay Arora, co-promoter of Blue Jet Healthcare, plans to sell a 3.42% stake in the company through an Offer for Sale (OFS). The floor price for the stake sale is set at 675.00 rupees per share. This move could potentially change the company's shareholding structure, affect market sentiment, increase stock liquidity, and attract new investors.
 no imag found
31Jul 25
BlueJet Healthcare Secures 102.48-Acre Land for Massive Expansion in Andhra Pradesh
Blue Jet Healthcare has acquired 102.48 acres of industrial land in Anakapalli District, Andhra Pradesh, for INR 41.87 crores. The company plans to invest up to INR 1,000 crores in Phase I to build a state-of-the-art manufacturing facility with a capacity of 1,000 KL. The project, expected to be operational by FY 2028-29, will be financed through internal accruals, equity, and debt. This expansion aims to support growth, enter new product verticals, and strengthen strategic relationships in the pharmaceutical industry.
 no imag found
31Jul 25
Blue Jet Healthcare Secures 102.48-Acre Land for INR 1,000 Crore Manufacturing Facility in Andhra Pradesh
Blue Jet Healthcare Limited has acquired 102.48 acres of industrial land in Anakapalli District, Andhra Pradesh, for INR 41.87 crore. The company plans to invest up to INR 1,000 crore in Phase I to build a facility with a manufacturing capacity of 1,000 KL, expected to be operational by FY 2028-29. This expansion aims to support growth, enter new product verticals, and strengthen industry relationships. The project will be financed through internal accruals, equity, and debt.
 no imag found
22Jul 25
Blue Jet Healthcare Reports 141% Surge in Q1 Profit, Revenue More Than Doubles
Blue Jet Healthcare Limited, a specialty pharmaceutical manufacturer, reported impressive Q1 results. Profit soared 141% to ₹911.70 crore, while revenue more than doubled to ₹3,547.58 crore. EBITDA grew 173.3% to ₹1,210.00 crore, with margin improving to 34.1%. Growth was primarily driven by higher sales in Pharma Intermediates & API. Despite strong performance, shares fell 10% due to sequential decline in EBITDA and margins.
 no imag found
14May 25
Blue Jet Healthcare's Q4 Profit Soars to ₹1.1 Billion, Marking Significant Growth
Blue Jet Healthcare, a key player in the pharmaceutical sector, announced a significant increase in its fourth-quarter net profit. The company reported a net profit of ₹1.10 billion, up from ₹396.00 million in the same quarter last year, representing a year-over-year growth of 177.78%. This substantial profit growth demonstrates the company's strong financial performance and could potentially impact its market position and investor confidence positively.
 no imag found
09Apr 25
Blue Jet Healthcare Expands into Chemical Intermediate Exports for Contrast Media Production
Blue Jet Healthcare has begun exporting a key chemical intermediate for gadolinium-based contrast media production in Q4FY25. This initiative is part of a collaboration with a European innovator partner. While not directly handling gadolinium, the company is now indirectly involved in the contrast media market, potentially opening new revenue streams. This move signifies Blue Jet's strategy to diversify its product portfolio and expand its global presence in the pharmaceutical ingredients market.
 no imag found
Blue Jet Healthcare
411.45
+4.75
(+1.17%)
1 Year Returns:-50.06%
Industry Peers
Sun Pharmaceutical
1,695.10
(-0.44%)
Divis Laboratories
6,024.50
(-1.91%)
Torrent Pharmaceuticals
3,939.00
(-0.94%)
Cipla
1,330.00
(-0.25%)
Dr Reddys Laboratories
1,241.20
(-0.30%)
Lupin
2,173.70
(-2.02%)
Zydus Life Science
888.15
(-1.86%)
Mankind Pharma
2,060.20
(-0.97%)
Aurobindo Pharma
1,191.00
(+0.80%)
Alkem Laboratories
5,684.00
(+0.38%)